Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
KTTA Stock Summary
In the News
Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?
Pasithea Therapeutics (NASDAQ: KTTA ) stock is falling on Wednesday after the company's shares experienced major volatility on Tuesday. Investors watching KTTA stock will note that it closed out Tuesday up less than 1%.
Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?
Pasithea Therapeutics (NASDAQ: KTTA ) stock is rocketing higher on Monday after the biotechnology company announced results from two preclinical trials of PAS-004. The first study saw positive results from PAS-004 as a treatment for lung cancer.
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
-- Attendees may request 1 x 1 meeting with management at meetings@hcwco.com -- PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, announced today that Pasithea's management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference, to be held in New York City, September 11-13.
Hot Penny Stocks For Your January 2022 Watchlist
Making a penny stocks watchlist for January? Check these three out The post Hot Penny Stocks For Your January 2022 Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Top Penny Stocks to Watch During Today's Bull Run
Can these three penny stocks continue to make gains next month? The post Top Penny Stocks to Watch During Today's Bull Run appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
KTTA Stock Alert: 6 Things to Know About Pasithea Therapeutics as Shares Soar Today
Pasithea Therapeutics (KTTA) stock is heading higher on heavy trading Thursday even without any recent news from the biotech company. The post KTTA Stock Alert: 6 Things to Know About Pasithea Therapeutics as Shares Soar Today appeared first on InvestorPlace.
Pasithea Therapeutics (KTTA) Stock: Why The Price Jumped Today
The stock price of Pasithea Therapeutics Corp (NASDAQ: KTTA) increased by over 25% pre-market today. This is why it happened.
Hot Penny Stocks Today: Why Is KTTA Stock Moving?
Shares of penny stock KTTA are on the move and here's what's going on. The post Hot Penny Stocks Today: Why Is KTTA Stock Moving?
Pasithea Therapeutics (KTTA) Stock: Why The Price Surged Today
The stock price of Pasithea Therapeutics Corp (NASDAQ: KTTA) increased by over 135% pre-market today. This is why it happened.
Pasithea Therapeutics Opens its First Ketamine Therapy Clinic in the United Kingdom
Pasithea Clinics partners with ZEN Healthcare – a network of health clinics in Central London – to offer ketamine infusion therapy for the treatment of mental health disorders Ketamine in sub-anesthetic doses has shown to be highly effective at treating some psychiatric disorders, such as treatment resistant depression and post-traumatic stress disorder
KTTA Financial details
KTTA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|
2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0.02 | |
Net income per share | -0.06 | -0.21 | -0.52 | |
Operating cash flow per share | -0.06 | -0.31 | -0.58 | |
Free cash flow per share | -0.06 | -0.31 | -0.66 | |
Cash per share | 0.35 | 5.09 | 1.31 | |
Book value per share | 0.35 | 4.94 | 1.68 | |
Tangible book value per share | 0.35 | 4.94 | 1.29 | |
Share holders equity per share | 0.35 | 4.94 | 1.68 | |
Interest debt per share | 0 | 0 | 0.04 | |
Market cap | 49.05M | 368.33M | 324.23M | |
Enterprise value | 48.81M | 315.36M | 292.01M | |
P/E ratio | -1.2K | -169.42 | -24.83 | |
Price to sales ratio | 0 | 24.45K | 666.38 | |
POCF ratio | -1.27K | -116.04 | -22.27 | |
PFCF ratio | -1.27K | -115.26 | -19.41 | |
P/B Ratio | 203.23 | 7.16 | 7.63 | |
PTB ratio | 203.23 | 7.16 | 7.63 | |
EV to sales | 0 | 20.94K | 600.16 | |
Enterprise value over EBITDA | -1.19K | -69.99 | -19.81 | |
EV to operating cash flow | -1.26K | -99.36 | -20.05 | |
EV to free cash flow | -1.26K | -98.69 | -17.49 | |
Earnings yield | 0 | -0.01 | -0.04 | |
Free cash flow yield | 0 | -0.01 | -0.05 | |
Debt to equity | 0 | 0 | 0.02 | |
Debt to assets | 0 | 0 | 0.02 | |
Net debt to EBITDA | 5.95 | 11.75 | 2.19 | |
Current ratio | 37.55 | 119.17 | 18.15 | |
Interest coverage | 0 | -8.87K | -145.26K | |
Income quality | 0.94 | 1.46 | 1.04 | |
Dividend Yield | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 5.48 | |
Intangibles to total assets | 0 | 0 | 0.22 | |
Capex to operating cash flow | 0 | 0.01 | 0.15 | |
Capex to revenue | 0 | -1.43 | -4.4 | |
Capex to depreciation | 0 | -15.59 | -66.06 | |
Stock based compensation to revenue | 0 | 31.29 | 1.14 | |
Graham number | 0.68 | 4.82 | 4.42 | |
ROIC | 0.08 | -0.09 | -0.31 | |
Return on tangible assets | -0.17 | -0.04 | -0.37 | |
Graham Net | 0.34 | 4.91 | 1.22 | |
Working capital | 241.36K | 52.85M | 32.2M | |
Tangible asset value | 241.36K | 51.42M | 32.65M | |
Net current asset value | 241.36K | 51.4M | 31.39M | |
Invested capital | 0 | 0 | 0.02 | |
Average receivables | 0 | 0 | 151.07K | |
Average payables | 0 | 226.94K | 1.03M | |
Average inventory | 0 | 0 | 0.5 | |
Days sales outstanding | 0 | 0 | 226.65 | |
Days payables outstanding | 0 | 9.45K | 5.21K | |
Days of inventory on hand | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 1.61 | |
Payables turnover | 0 | 0.04 | 0.07 | |
Inventory turnover | 0 | 0 | 113.2K | |
ROE | -0.17 | -0.04 | -0.31 | |
Capex per share | 0 | 0 | -0.08 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.01 | 0.01 | 0 | 0 | 0 | |
Net income per share | -0.2 | -0.15 | -10.55 | -0.14 | -0.14 | |
Operating cash flow per share | -0.2 | -0.17 | -0.12 | -0.13 | -0.11 | |
Free cash flow per share | -0.2 | -0.25 | -0.12 | -0.13 | -0.1 | |
Cash per share | 1.6 | 1.31 | 1.15 | 1.02 | 0.78 | |
Book value per share | 1.76 | 1.68 | 1.5 | 1.36 | 1.13 | |
Tangible book value per share | 1.62 | 1.29 | 1.13 | 1 | 0.76 | |
Share holders equity per share | 1.76 | 1.68 | 1.5 | 1.36 | 1.13 | |
Interest debt per share | 0.05 | 0.04 | 0.03 | 0.02 | 0.02 | |
Market cap | 669.03M | 324.23M | 195.55M | 256.05M | 241.55M | |
Enterprise value | 627.61M | 292.01M | 166.36M | 229.97M | 222.35M | |
P/E ratio | -31.82 | -20.77 | -0.18 | -17.01 | -16.72 | |
Price to sales ratio | 3.06K | 1.35K | 0 | 0 | 0 | |
POCF ratio | -127.71 | -73.38 | -61.07 | -73.59 | -90.99 | |
PFCF ratio | -123.07 | -52.23 | -60.05 | -73.53 | -91.77 | |
P/B Ratio | 14.3 | 7.63 | 5 | 7.19 | 8.51 | |
PTB ratio | 14.3 | 7.63 | 5 | 7.19 | 8.51 | |
EV to sales | 2.87K | 1.21K | 0 | 0 | 0 | |
Enterprise value over EBITDA | -160.97 | -70.12 | -54.53 | -60.84 | -58.68 | |
EV to operating cash flow | -119.8 | -66.09 | -51.95 | -66.09 | -83.76 | |
EV to free cash flow | -115.45 | -47.04 | -51.09 | -66.04 | -84.48 | |
Earnings yield | -0.01 | -0.01 | -1.41 | -0.01 | -0.01 | |
Free cash flow yield | -0.01 | -0.02 | -0.02 | -0.01 | -0.01 | |
Debt to equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | |
Debt to assets | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | |
Net debt to EBITDA | 10.62 | 7.74 | 9.57 | 6.9 | 5.07 | |
Current ratio | 29.37 | 18.15 | 14.66 | 12.58 | 10.16 | |
Interest coverage | -12.68 | -49.81K | -502.9 | 0 | 0 | |
Income quality | 1.14 | 0.86 | 0.98 | 0.97 | 0.73 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 5.3 | 5.76 | 0 | 0 | 0 | |
Intangibles to total assets | 0.08 | 0.22 | 0.23 | 0.25 | 0.31 | |
Capex to operating cash flow | 0.04 | 0.4 | 0.02 | 0 | -0.01 | |
Capex to revenue | -0.9 | -7.43 | 0 | 0 | 0 | |
Capex to depreciation | -11.84 | 18.44K | -0.33 | -0.02 | 0.14 | |
Stock based compensation to revenue | -1.36 | 0.65 | 0 | 0 | 0 | |
Graham number | 2.8 | 2.42 | 18.88 | 2.1 | 1.91 | |
ROIC | -0.1 | -0.09 | -6.71 | -0.1 | -0.12 | |
Return on tangible assets | -0.11 | -0.11 | -8.5 | -0.13 | -0.17 | |
Graham Net | 1.49 | 1.22 | 1.05 | 0.94 | 0.71 | |
Working capital | 42.96M | 32.2M | 28.99M | 25.81M | 18.73M | |
Tangible asset value | 42.92M | 32.65M | 29.46M | 26.07M | 19.01M | |
Net current asset value | 41.65M | 31.39M | 28.2M | 25.48M | 18.49M | |
Invested capital | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | |
Average receivables | 0 | 151.07K | 158.96K | 69.14K | 108.75K | |
Average payables | 627.98K | 1.44M | 1.53M | 1.69M | 963.02K | |
Average inventory | 0 | 0.5 | 460.24K | 867.53K | 899.82K | |
Days sales outstanding | 0 | 112.96 | 0 | 0 | 0 | |
Days payables outstanding | 1.31K | 111.08K | 800.83 | 1.06K | 0 | |
Days of inventory on hand | 0 | 0.07 | 509.24 | 449.17 | 546.4 | |
Receivables turnover | 0 | 0.8 | 0 | 0 | 0 | |
Payables turnover | 0.07 | 0 | 0.11 | 0.08 | 0 | |
Inventory turnover | 0 | 1.31K | 0.18 | 0.2 | 0.16 | |
ROE | -0.11 | -0.09 | -7.03 | -0.11 | -0.13 | |
Capex per share | -0.01 | -0.07 | 0 | 0 | 0 |
KTTA Frequently Asked Questions
What is Pasithea Therapeutics Corp. stock symbol ?
Pasithea Therapeutics Corp. is a US stock , located in Miami beach of Fl and trading under the symbol KTTA
What is Pasithea Therapeutics Corp. stock quote today ?
Pasithea Therapeutics Corp. stock price is $7.15 today.
Is Pasithea Therapeutics Corp. stock public?
Yes, Pasithea Therapeutics Corp. is a publicly traded company.